[1]褚春沐.雷贝拉唑治疗进展性缺血性脑卒中的价值[J].医学信息,2022,35(14):122-124.[doi:10.3969/j.issn.1006-1959.2022.14.030]
　CHU Chun-mu.Value of Rabeprazole in Treatment of Progressive Ischemic Stroke[J].Medical Information,2022,35(14):122-124.[doi:10.3969/j.issn.1006-1959.2022.14.030]
点击复制

雷贝拉唑治疗进展性缺血性脑卒中的价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年14期
页码:
122-124
栏目:
药物与临床
出版日期:
2022-07-15

文章信息/Info

Title:
Value of Rabeprazole in Treatment of Progressive Ischemic Stroke
文章编号:
1006-1959（2022）14-0122-03
作者:
褚春沐
（佳木斯市中心医院神经内科，黑龙江 佳木斯 154002）
Author(s):
CHU Chun-mu
(Department of Neurology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
雷贝拉唑; 缺血性脑卒中; 血小板聚集率; 消化道出血
Keywords:
Rabeprazole; Ischemic stroke; Platelet aggregation rate; Gastrointestinal bleeding
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2022.14.030
文献标志码:
A
摘要:
目的 观察雷贝拉唑治疗进展性缺血性脑卒中的临床效果。方法 选取2020年8月-2021年6月我院接诊的84例进展性缺血性脑卒中患者为研究对象，采用随机数字表法分为对照组和观察组，各42例。对照组采用常规治疗，观察组在对照组基础上给予雷贝拉唑治疗，比较两组神经功能缺损（NIHSS）评分、改良预后（mRS）评分、预后良好率、血小板最大聚集率、消化道出血发生率及不良反应发生情况。结果 两组NIHSS评分、mRS评分均低于治疗前，且观察组低于对照组（P＜0.05）；观察组预后良好率为83.33%，高于对照组的71.42%（P＜0.05）；两组血小板最大聚集率比较，差异无统计学意义（P＞0.05）；观察组消化道出血发生率为2.38%，低于对照组21.42%（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 雷贝拉唑治疗进展性缺血性脑卒中效果良好，对抗血小板聚集作用无影响，可降低消化道出血发生率，降低神经功能缺损评分，改善患者预后。
Abstract:
Objective To observe the clinical effect of rabeprazole in the treatment of progressive ischemic stroke.Methods A total of 84 patients with progressive ischemic stroke admitted to our hospital from August 2020 to June 2021 were selected as the research subjects. They were divided into control group and observation group by random number table method, 42 cases in each group. The control group was treated with routine treatment, and the observation group was treated with rabeprazole on the basis of the control group. The neurological deficit (NIHSS) score, modified prognosis (mRS) score, good prognosis rate, platelet maximum aggregation rate, incidence of gastrointestinal bleeding and adverse reactions were compared between the two groups.Results The NIHSS score and mRS score of the two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05). The good prognosis rate of the observation group was 83.33%, which was higher than that 71.42% of the control group (P<0.05). There was no significant difference in the maximum platelet aggregation rate between the two groups (P>0.05). The incidence of gastrointestinal bleeding in the observation group was 2.38%, which was lower than 21.42% in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Rabeprazole is effective in the treatment of progressive ischemic stroke, and has no effect on antiplatelet aggregation. It can reduce the incidence of gastrointestinal bleeding, reduce the neurological deficit score, and improve the prognosis of patients, which is worthy of clinical application.

参考文献/References:

[1]陈英道,李海宁,张岐平,等.低分子肝素联合依达拉奉治疗进展性脑梗死的临床价值观察[J].中国处方药,2020,18(5):57-59.[2]李凤芹.氯吡格雷联合阿司匹林治疗进展性缺血性脑卒中的效果观察[J].河南医学研究,2017,26(9):1645-1646.[3]刘晓锐.丁苯酞氯化钠注射液联合rt-PA静脉溶栓治疗47例急性缺血性脑卒中患者的短期临床研究[J].国际医药卫生导报,2019,25(3):404-408. [4]孙国民.阿司匹林联合氯吡格雷治疗进展性缺血性脑卒中的效果评价[J].中国处方药,2017,15(10):51-52. [5]王雪婷,王莹,韩越,等.抗焦虑治疗控制进展性缺血性脑卒中发生的临床研究[J].哈尔滨医科大学学报,2016,50(5):449-451. [6]李晓红,刘文栋.血栓通注射液联合氯吡格雷治疗进展性缺血性脑卒中的临床研究[J].中西医结合心脑血管病杂志,2018,16(7):986-989. [7]赵阳,郑辑英.进展性缺血性脑卒中危险因素的临床研究[J].中西医结合心脑血管病杂志,2016,14(8):820-824. [8]张皓翔,王志恒,张梦培,等.基于数据挖掘的中成药治疗缺血性脑卒中恢复期的临床用药研究[J].世界中医药,2021,16(9):1438-1442,1449. [9]世界华人检验与病理医师协会,中国医师协会检验医师分会心血管检验医学专业委员会.血小板功能检测在急性冠脉综合征患者抗血小板治疗中的应用专家共识[J].中华医学杂志,2018,98(22):1743-1751. [10]闫丽,经屏.替罗非班治疗急性缺血性脑卒中的临床疗效及其对神经功能和血小板功能的影响[J].实用心脑肺血管病杂志,2018,26(11):103-105．[11]陈欣,关兰芳,马赟英,等.进展性缺血性脑卒中危险因素及其预测价值研究[J].卒中与神经疾病,2016,23(6):392-395.[12]张立芳,李博.丁苯酞联合替罗非班治疗进展性脑卒中的临床疗效及对血小板的影响[J].广西医科大学学报,2019,36(3):399-403．[13]焦冬生,赵全,钱时德,等.替罗非班联合奥扎格雷纳治疗进展性脑卒中的临床疗效及其对血小板水平影响分析[J].贵州医药,2018,42(1):39-41．[14]姚涛,任明山,李淮玉．缺血性脑卒中急性 期 超 敏C－反应蛋白水平变化与进展性卒中的相关性[J].实用医学杂志,2016,32(5):735-738．[15]邱峰,吴越,曹辉,等.重度大脑中动脉狭窄所致内分水岭梗死患者早期脑卒中进展的相关危险因素分析[J].医学研究生学报,2017,30(10):1065-1070．[16]车雁芳,杨国华,师春梅,等.长春西汀联合奥扎格雷钠治疗进展性缺血性脑卒中临床疗效及其对血小板活化的影响[J].黑龙江医学,2015,39(4):390-392.[17]张明池.依达拉奉联合奥扎格雷钠治疗缺血性脑卒中的疗效及对患者炎性因子与血液流变学的影响[J].慢性病学杂志,2017,18(4):422-424.[18]朱林,王治国,王树桢,等.低分子肝素钙联合氯吡格雷治疗进展性缺血性脑卒中的临床研究[J].广西医科大学学报,2016,33(2):280-282.[19]抗栓治疗消化道损伤防治专家组.抗栓治疗消化道损伤防治中国专家建议(2016·北京)[J].中华内科杂志,2016,55(7):564-567.[20]罗叶婷,叶鹏,杨云珠.雷贝拉唑在进展性缺血性脑卒中治疗中的价值探讨[J].中风与神经疾病杂志,2019,36(9):839-841.

相似文献/References:

[1]夏 铭,张正坤,曾海龙,等.四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析[J].医学信息,2018,31(11):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
　XIA Ming,ZHANG Zheng-kun,ZENG Hai-long,et al.Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer[J].Medical Information,2018,31(14):18.[doi:10.3969/j.issn.1006-1959.2018.11.006]
[2]罗宜辉,刘代华.益生菌联合四联方案根除幽门螺杆菌的临床研究[J].医学信息,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
　LUO Yi-hui,LIU Dai-hua.Clinical Study on the Eradication of Helicobacter Pylori by Probiotics Combined with Quadruple Regimen[J].Medical Information,2018,31(14):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
[3]上官建辉,唐春燕.老年性缺血性脑卒中后抑郁干预治疗对神经功能恢复的疗效分析[J].医学信息,2019,32(03):125.[doi:10.3969/j.issn.1006-1959.2019.03.040]
　SHANGGUAN Jian-hui,TANG Chun-yan.Effect of Intervention Therapy on Neurologic Function Recovery after Senile Ischemic Cerebral Apoplexy[J].Medical Information,2019,32(14):125.[doi:10.3969/j.issn.1006-1959.2019.03.040]
[4]宫园园.LDL、Hcy、D-二聚体及颈动脉粥样硬化与急性缺血性脑卒中相关性研究[J].医学信息,2019,32(05):117.[doi:10.3969/j.issn.1006-1959.2019.05.036]
　GONG Yuan-yuan.Correlation between LDL,Hcy,D-dimer and Carotid Atherosclerosis and Acute Ischemic Stroke[J].Medical Information,2019,32(14):117.[doi:10.3969/j.issn.1006-1959.2019.05.036]
[5]张利山.缺血性脑卒中后癫痫发作的临床特点及治疗研究[J].医学信息,2019,32(18):38.[doi:10.3969/j.issn.1006-1959.2019.18.013]
　ZHANG Li-shan.Study on the Clinical Features and Treatment of Seizures after Ischemic Stroke[J].Medical Information,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.18.013]
[6]张志颖.老年女性内源性循环雌二醇和卒中风险的研究[J].医学信息,2019,32(22):84.[doi:10.3969/j.issn.1006-1959.2019.22.025]
　ZHANG Zhi-ying.Study on Endogenous Circulating Estradiol and Stroke Risk in Elderly Women[J].Medical Information,2019,32(14):84.[doi:10.3969/j.issn.1006-1959.2019.22.025]
[7]韩付金.雷贝拉唑肠溶胶囊联合铝碳酸镁咀嚼片用于难治性良性胃溃疡的疗效[J].医学信息,2020,33(20):141.[doi:10.3969/j.issn.1006-1959.2020.20.043]
　HAN Fu-jin.Efficacy of Rabeprazole Enteric-coated Capsules Combined with Hydrotalcite Chewable Tablets for Refractory Benign Gastric Ulcer[J].Medical Information,2020,33(14):141.[doi:10.3969/j.issn.1006-1959.2020.20.043]
[8]肖 伟,余巨明.缺血性卒中后认知障碍相关可控因素的研究进展[J].医学信息,2020,33(21):35.[doi:10.3969/j.issn.1006-1959.2020.21.011]
　XIAO Wei,YU Ju-ming.Research Progress on the Related Controllable Factors of Cognitive Impairment After Ischemic Stroke[J].Medical Information,2020,33(14):35.[doi:10.3969/j.issn.1006-1959.2020.21.011]
[9]张新艳,姜国清.颈动脉超声及CT测定粥样斑块诊断缺血性脑卒中的作用[J].医学信息,2020,33(21):160.[doi:10.3969/j.issn.1006-1959.2020.21.050]
　ZHANG Xin-yan,JIANG Guo-qing.The Role of Carotid Ultrasound and CT in the Diagnosis of Cerebral Ischemic Stroke[J].Medical Information,2020,33(14):160.[doi:10.3969/j.issn.1006-1959.2020.21.050]
[10]张运林.铝碳酸镁片联合雷贝拉唑Hp感染合并活动性消化性溃疡的安全性[J].医学信息,2020,33(24):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]
　ZHANG Yun-lin.The Safety of Hydrotalcite Tablets Combined with Rabeprazole Hp Infection with Active Peptic Ulcer[J].Medical Information,2020,33(14):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]

更新日期/Last Update: 1900-01-01